Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 160Lymphoid 80Other hematologic neoplasm 40Thoracic 7Myeloid 6Genitourinary 6Gastrointestinal 6CNS 6Sarcoma 5Dermatologic 5Head & Neck 4Endocrine 2Classical hematology 2Breast 2Tumor-Agnostic 1Gynecologic 1

Conditions

Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 151Carboplatin 123Bevacizumab 86Cisplatin 66pembrolizumab 58Taxes 51Gemcitabine 51liposomal doxorubicin 38Topotecan 37olaparib 30Immunoglobulin G 27Disulfides 26Cyclophosphamide 24Brachytherapy 22Docetaxel 21human papillomavirus vaccine, L1 type 16, 18 20Platinum 19niraparib 181,2-diaminocyclohexaneplatinum II citrate 18rucaparib 17Nivolumab 17Magnetic Resonance Spectroscopy 17durvalumab 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 16Doxorubicin 16Radiotherapy, Intensity-Modulated 14Radiation 13Albumin-Bound Paclitaxel 13fludarabine phosphate 12fludarabine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bortezomib × Gynecologic × Clear all
NCT00023712 2019-07-30

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
58 enrolled 14 charts
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡